Download video

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies

1.4K views

PeerView Oncology

2 years ago

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies
58:27
Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies
by PeerView Oncology
The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
58:30
The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
by PeerView Oncology
Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others
56:23
Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others
by PeerView Oncology
HER3 as a New Target in the Oncology field
1:13
HER3 as a New Target in the Oncology field
by CAST PHARMA
HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors
51:24
HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors
by PeerView Oncology
Moving Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, GI, Lung \& Other Cancers
1:30:06
Moving Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, GI, Lung \& Other Cancers
by PeerView Oncology
Understanding HER2 Alterations in Advanced Non-Squamous NSCLC
57:49
Understanding HER2 Alterations in Advanced Non-Squamous NSCLC
by CAP TODAY
Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
33:28
Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
by Touch Medical Media
GRACEcast - Treatment options for patients with advanced NSCLC and a HER2- ERBB2 mutation
6:31
GRACEcast - Treatment options for patients with advanced NSCLC and a HER2- ERBB2 mutation
by GRACE - Global Resource for Advancing Cancer Education
Drs. Jänne, Garon, \& Yu, discuss the latest #NSCLC updates from #TTLC22 - https:\/\/bit.ly\/355e4Dq
1:00:29
Drs. Jänne, Garon, \& Yu, discuss the latest #NSCLC updates from #TTLC22 - https:\/\/bit.ly\/355e4Dq
by PeerView Oncology
HER2 Targeted Therapy for Treatment of NSCLC
17:15
HER2 Targeted Therapy for Treatment of NSCLC
by OncLive
Strategies to Target HER2 in Lung Cancer
1:45
Strategies to Target HER2 in Lung Cancer
by American Lung Association
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
36:45
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
by Touch Medical Media
The future of NSCLC treatment
3:28
The future of NSCLC treatment
by VJOncology
Developments in ADCs for NSCLC
1:59
Developments in ADCs for NSCLC
by VJOncology
Drs. Johnson, Levy, \& Yu discuss the latest Lung Cancer updates from #WCLC21: https:\/\/bit.ly\/3gOriYo
1:02:54
Drs. Johnson, Levy, \& Yu discuss the latest Lung Cancer updates from #WCLC21: https:\/\/bit.ly\/3gOriYo
by PeerView Oncology
Dr. Bunn on Targeting HER3 in NSCLC
1:10
Dr. Bunn on Targeting HER3 in NSCLC
by OncLive
Treating HER2 Exon-20 Insertion NSCLC with Trastuzumab Deruxtecan - Case Based Panel Discussion
6:18
Treating HER2 Exon-20 Insertion NSCLC with Trastuzumab Deruxtecan - Case Based Panel Discussion
by GRACE - Global Resource for Advancing Cancer Education
HER2 Mutation Positive NSCLC
2:54
HER2 Mutation Positive NSCLC
by GRACE - Global Resource for Advancing Cancer Education